istock-896469402-stuart-ritchie

Stuart Ritchie / iStockphoto.com

30 August 2018Americas

FDA warns 21 websites over misbranded opioid drugs

The US Food and Drug Administration (FDA) has warned 21 websites over the illegal marketing of misbranded versions of opioid medications.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

FDA and DEA warn over sale of misbranded opioid drugs

1 October 2019 The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines.

Emergent BioSolutions to buy Adapt Pharma for $735m

30 August 2018 Life sciences company Emergent BioSolutions announced plans to acquire Adapt Pharma earlier this week, in what the company said was an effort to combat the public health threat from opioid overdose.

More on this story

FDA and DEA warn over sale of misbranded opioid drugs

1 October 2019 The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines.

Emergent BioSolutions to buy Adapt Pharma for $735m

30 August 2018 Life sciences company Emergent BioSolutions announced plans to acquire Adapt Pharma earlier this week, in what the company said was an effort to combat the public health threat from opioid overdose.

More on this story

FDA and DEA warn over sale of misbranded opioid drugs

1 October 2019 The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines.

Emergent BioSolutions to buy Adapt Pharma for $735m

30 August 2018 Life sciences company Emergent BioSolutions announced plans to acquire Adapt Pharma earlier this week, in what the company said was an effort to combat the public health threat from opioid overdose.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB